Collaboration Between Rakuten Medical and LOTTE Biologics Enhances Global Oncology Manufacturing

Partnership Announcement

Rakuten Medical, Inc. and LOTTE Biologics have recently entered into a significant contract manufacturing agreement aimed at advancing the biopharmaceutical sector, particularly in oncology. This collaboration was officially announced at the prestigious J.P. Morgan Healthcare Conference held in San Francisco. The partnership is set to enhance Rakuten Medical’s production capabilities, especially for its innovative photoimmunotherapy treatment utilizing the Alluminox® platform.

Enhancing Oncology Therapies

Under this agreement, LOTTE Biologics will assume the role of a key supplier by providing advanced manufacturing services, specifically focusing on monoclonal antibody intermediates and their respective conjugates. This will directly support Rakuten Medical’s ongoing global clinical development efforts and future commercialization plans.

Rakuten Medical has made remarkable strides in the field of oncology with its proprietary photoimmunotherapy technology. This technology is designed to selectively identify and target solid tumor cells. The mechanism involves the use of light-activated agents combined with antibodies that enable precise destruction of tumor cells when exposed to light. Currently, this therapy holds approval for recurrent head and neck cancer in Japan and continues to gain traction with expanded site adoption and consistent growth in treatment numbers yearly.

Moreover, Rakuten Medical is conducting a global Phase 3 clinical trial encompassing multiple regions including the United States, Taiwan, Japan, with plans for future trials in Ukraine and Poland. This accelerated pace in clinical trials is indicative of the soaring demand for Rakuten Medical's bioconjugates in the global market. Additionally, the company has plans to initiate a Phase 1 clinical trial in Japan this year, focusing on treating solid tumors beyond just head and neck cancer.

LOTTE Biologics: A Growing Force in Biomanufacturing

LOTTE Biologics, which was founded in 2022 and boasts its headquarters in Seoul, South Korea, is quickly making a name for itself as a global Contract Development and Manufacturing Organization (CDMO). The organization has notably broadened its capabilities in the production of monoclonal and multispecific antibodies, as well as antibody-drug conjugates (ADCs), a critical area for advancing cancer therapies.

The specialized ADC manufacturing facility situated at the Syracuse Bio Campus in New York is equipped with cutting-edge technology dedicated to ADC production. This enables LOTTE Biologics to furnish high-quality manufacturing services, ensuring compliance with global regulatory standards and a reliable supply chain for its clients. LOTTE Biologics has succeeded in securing over 62 regulatory approvals worldwide, bolstering its reputation in the industry.

To further boost its production capacity, LOTTE Biologics is in the process of constructing three state-of-the-art bio plants at the Songdo Bio Campus in South Korea. Each of these plants is designed to include multiple 15,000 L stainless steel bioreactors aimed at commercial production, ensuring that the company is well-prepared to meet the increasing demand for biopharmaceuticals.

A Vision for the Future

LOTTE Biologics operates with a clear vision dubbed 'Possibilities Beyond Limits', striving to establish itself as a long-term, trusted partner in the biopharmaceutical industry. The company emphasizes support for its clients' therapeutic programs, focusing on effective scale-up and dependable manufacturing execution.

In summation, the strategic collaboration between Rakuten Medical and LOTTE Biologics promises to elevate the standards of biopharmaceutical manufacturing, particularly in the oncology sector. This partnership is hailed not only as a milestone for the involved companies but also potentially as a game-changer in how innovative cancer therapies are developed and made accessible to patients around the globe. As both companies advance with their plans, ongoing developments will be closely monitored by industry stakeholders, with hope for significant contributions to the field of cancer treatment.